<DOC>
	<DOCNO>NCT00496730</DOCNO>
	<brief_summary>Prevalence metabolic syndrome korea increase . There clinical trial target increase population like metabolic syndrome patient Vytorin® korea . Therefore trial help evaluate lipid lower effect Vytorin® asian population metabolic syndrome .</brief_summary>
	<brief_title>A Multicenter , Randomized , Open Label Study Evaluate Lipid Lowering Efficacy Safety Vytorin® 10/20 vs. Atorvastatin 10mg Hypercholesterolemia Patients With Metabolic Syndrome Korea ( 0653A-129 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Diagnosis metabolic syndrome accord 2005 American Heart Association/National Heart , Lung Blood Institute ( AHA/NHLBI ) scientific statement No history diabetes 100 &lt; =LDLC &lt; =250 mg/dl Myocardial Infarction , coronary artery bypass surgery , angioplasty within 3 month Congestive heart failure define New York Heart Association ( NYHA ) class III IV Uncontrolled endocrine metabolic disease know influence serum lipid lipoproteins Uncontrolled hypertension Unstable angina</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metabolic Disorder</keyword>
</DOC>